Articles published by Cybin Inc.
![](https://mms.businesswire.com/media/20230712990239/en/1839271/22/Cybin_Side_Logo.jpg)
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
July 12, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230630213508/en/1832427/22/Cybin_Side_Logo.jpg)
Cybin to Participate in PSYCH Symposium London 2023
June 30, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230629018977/en/1832281/22/Cybin_Side_Logo.jpg)
![](https://mms.businesswire.com/media/20230627133339/en/1829888/22/Cybin_Side_Logo.jpg)
![](https://mms.businesswire.com/media/20230627257777/en/1828670/22/Cybin_Side_Logo.jpg)
![](https://mms.businesswire.com/media/20230621688793/en/1824309/22/Cybin_Side_Logo_%28004%29.jpg)
![](https://mms.businesswire.com/media/20230608005341/en/1814212/22/Cybin_Side_Logo_%28004%29.jpg)
![](https://mms.businesswire.com/media/20230605005183/en/1810010/22/Cybin_Side_Logo_%28004%29.jpg)
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
June 05, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230601005347/en/1807885/22/Cybin_Side_Logo_%28004%29.jpg)
Cybin to Present at the Jefferies Healthcare Conference
June 01, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230530005628/en/1806015/22/Cybin_Side_Logo_%28004%29.jpg)
![](https://mms.businesswire.com/media/20230524005312/en/1801826/22/Cybin_Side_Logo.jpg)
![](https://mms.businesswire.com/media/20230509005435/en/1787255/22/Cybin_Side_Logo_%28004%29.jpg)
![](https://mms.businesswire.com/media/20230427005807/en/1776977/22/Cybin_Side_Logo.jpg)
![](https://mms.businesswire.com/media/20230412005176/en/1761253/22/Cybin_Side_Logo_%28004%29.jpg)
![](https://mms.businesswire.com/media/20230308005203/en/1732849/22/Cybin_Side_Logo_%28004%29.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20230228005438/en/1724443/22/Cybin_Side_Logo_%28004%29.jpg)
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
February 28, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230222006011/en/1720701/22/Cybin_Side_Logo_%28004%29.jpg)
Cybin Announces Streamlined Clinical Alignment
February 22, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230214005365/en/1712809/22/Cybin_Side_Logo_%28004%29.jpg)
![](https://mms.businesswire.com/media/20230201005381/en/1702140/22/Cybin_Side_Logo_%28004%29.jpg)
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
February 01, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230126005396/en/1696867/22/Cybin_Side_Logo_%28004%29.jpg)
Cybin to Host Virtual R&D Day on February 28, 2023
January 26, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230118005355/en/1688896/22/Cybin_Side_Logo_%28004%29.jpg)
![](https://mms.businesswire.com/media/20230112005249/en/1684085/22/Cybin_Side_Logo_%28004%29.jpg)
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
January 12, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20230108005044/en/1679914/22/Cybin_Side_Logo_%28004%29.jpg)
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
January 08, 2023
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20221220005245/en/1669343/22/Cybin_Side_Logo.jpg)
Cybin Highlights 2022 Accomplishments and Milestones
December 20, 2022
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20221206006027/en/1084589/5/Cybin_Primary_Logo_Blue_Final.jpg)
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
December 06, 2022
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20221114006182/en/1084589/5/Cybin_Primary_Logo_Blue_Final.jpg)
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
November 15, 2022
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20221114006074/en/1084589/5/Cybin_Primary_Logo_Blue_Final.jpg)
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
November 14, 2022
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20221110005310/en/1084589/5/Cybin_Primary_Logo_Blue_Final.jpg)
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
November 10, 2022
From Cybin Inc.
Via Business Wire
Tickers
CYBN
![](https://mms.businesswire.com/media/20221103005422/en/1084589/5/Cybin_Primary_Logo_Blue_Final.jpg)
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
November 03, 2022
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.